{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lin NU"],"funding":["NCI NIH HHS"],"pagination":["2623-31"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4534525"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(24)"],"pubmed_abstract":["Purpose
Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, human epidermal growth factor receptor 2-positive metastatic breast cancer (MBC). We tested the combination in the earlier-line setting and explored the predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) for clinical outcomes.Patients and methods
Two cohorts were enrolled (cohort 1: no prior trastuzumab for MBC and ≥ 1 year from adjuvant trastuzumab, if given; cohort 2: one to two lines of chemotherapy including trastuzumab for MBC and/or recurrence < 1 year from adjuvant trastuzumab). The primary end point was objective response rate by RECIST v1.0; secondary end points included clinical benefit rate (complete response plus partia"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)."],"pmcid":["PMC4534525"],"funding_grant_id":["P50 CA089393","CA089393","CA089393-10S1"],"pubmed_authors":["Hobday TJ","Nanda R","Falkson CI","Dees EC","Arteaga CL","Van den Abbeele AD","Yap JT","Rimawi MF","Winer EP","Mayer IA","Barry WT","Ryabin N","Guo H","Najita JS","Richardson AL","Lin NU","Wolff AC","Krop IE"],"additional_accession":[]},"is_claimable":false,"name":"Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).","description":"Purpose
Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, human epidermal growth factor receptor 2-positive metastatic breast cancer (MBC). We tested the combination in the earlier-line setting and explored the predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) for clinical outcomes.Patients and methods
Two cohorts were enrolled (cohort 1: no prior trastuzumab for MBC and ≥ 1 year from adjuvant trastuzumab, if given; cohort 2: one to two lines of chemotherapy including trastuzumab for MBC and/or recurrence < 1 year from adjuvant trastuzumab). The primary end point was objective response rate by RECIST v1.0; secondary end points included clinical benefit rate (complete response plus partia","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Aug","modification":"2025-04-03T22:29:25.541Z","creation":"2019-03-27T01:56:40Z"},"accession":"S-EPMC4534525","cross_references":{"pubmed":["26169615"],"doi":["10.1200/jco.2014.60.0353","10.1200/JCO.2014.60.0353"]}}